慢性肾脏病合并房颤患者的新型口服抗凝药应用
房颤在慢性肾脏病患者中患病率显著增高,且两者互为因果。新型口服抗凝药在轻中度肾功能不全患者中获益明确,但终末期肾病患者因被 pivotal 3 期试验排除而证据有限。本综述汇总现有数据并为不同 CKD 分期提供推荐。
要点
- CKD 3 期患者从口服抗凝治疗中获益可能优于肾功能正常者,但需按肾功能选择药物。
- NOACs 肾脏清除率各异,肾功能下降时蓄积和出血风险增加,需分期调整。
- 终末期肾病患者使用 NOACs 的证据主要来自观察性研究,缺乏 pivotal 3 期试验数据。
核心结论
- NOACs 可用于 CKD 合并房颤患者,但需根据肾功能分期选择药物并监测出血风险。
- CKD 3 期患者口服抗凝获益可能较肾功能正常者更显著。
- 晚期及终末期肾病患者的最佳抗凝策略仍不明确,需个体化决策。
研究设计与样本
- 综述总结了现有 NOACs 在 CKD 合并房颤患者中的疗效与安全性证据。
主要发现
- 房颤和 CKD 均增加卒中或系统性血栓栓塞风险,口服抗凝是房颤患者预防血栓事件的主要手段。
- NOACs 肾脏清除程度不一,CKD 尤其进展期患者蓄积和出血风险增加。
- 晚期及终末期肾病患者被所有 pivotal 3 期 NOACs 试验排除,相关证据有限。
临床怎么用
- 应根据 CKD 分期选择 NOACs 种类和剂量,并密切监测肾功能和出血风险。
- 对晚期 CKD 或终末期肾病患者,需综合评估血栓和出血风险后个体化抗凝。
局限性
- 晚期和终末期肾病患者缺乏 pivotal 3 期随机对照试验数据。
- 综述基于现有文献,未提供新的原始研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation (AF) is the most frequent arrhythmia in common clinical practice and its prevalence is markedly increased among patients with chronic kidney disease (CKD). The presence of CKD increases the incidence of AF and vice versa. Both AF and CKD increase the risk of stroke or systemic thromboembolism and oral anticoagulation is the mainstay for thromboembolic event prevention in patients with AF. Novel oral anticoagulants (NOACs) are nowadays often used in patients with AF and CKD, but they display a variable degree of renal elimination and the risk of accumulation and bleeding increases among patients with CKD in particular as kidney disease progresses. While recent data have demonstrated that patients with Stage 3 CKD benefit even more from oral anticoagulation therapies in comparison with patients with normal renal function, relatively little is known about the best choice of anticoagulation in patients with advanced and, in particular, end-stage renal disease, as these patients were excluded from all pivotal Phase 3 NOACs trials. This review summarizes current knowledge on the efficacy and safety of these agents in individuals with CKD and provides CKD stage-specific recommendations.
引用
- Stamellou E, Floege J. Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. Nephrol Dial Transplant. 2018. PMID: 29206932. doi:10.1093/ndt/gfx322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。